Mr Bourla does not say in the interview that COVID jabs are dangerous. The interview begins at the 35 seconds mark of the ...
At the JPM conference, Pfizer CEO Albert Bourla projected optimism, saying the market was overlooking the pharma company's ...
The pharma expects a modest financial headwind this year from changes to Medicare prescription drug benefits under the ...
U.S. drugmaker Pfizer is going "all in" to develop its experimental obesity drug and has been recruiting more experts in that ...
In a report released on January 21, Akash Tewari from Jefferies reiterated a Buy rating on Pfizer (PFE – Research Report). The company’s shares ...
The sale decreases Pfizer’s shareholding in the consumer-healthcare business to 7.3% of its issued share capital, down from ...
Hosted on MSN1d
Here's Why Pfizer (PFE) is a Strong Value StockTaking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. Featuring daily updates of ...
General side effects: tiredness, headache, muscle pain, chills, joint pain, fever, nausea, feeling unwell, swollen lymph ...
The general mood among these heavyweight investors is divided, with 33% leaning bullish and 50% bearish. Among these notable ...
Pfizer Inc. ( NYSE:PFE ) will increase its dividend from last year's comparable payment on the 7th of March to ...
Pfizer CEO Albert Bourla joins CNBC's 'Special Report' as President-elect Donald Trump is inaugurated as the 47th U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback